ATE458050T1 - Promotion oder inhibition von angiogenese und kardiovaskularisation - Google Patents

Promotion oder inhibition von angiogenese und kardiovaskularisation

Info

Publication number
ATE458050T1
ATE458050T1 AT99960624T AT99960624T ATE458050T1 AT E458050 T1 ATE458050 T1 AT E458050T1 AT 99960624 T AT99960624 T AT 99960624T AT 99960624 T AT99960624 T AT 99960624T AT E458050 T1 ATE458050 T1 AT E458050T1
Authority
AT
Austria
Prior art keywords
polypeptides
present
compositions
cardiovascularization
disorders
Prior art date
Application number
AT99960624T
Other languages
English (en)
Inventor
Avi Ashkenazi
Kevin Baker
Napoleone Ferrara
Hanspeter Gerber
Kenneth Hillan
Audrey Goddard
Paul Godowski
Austin Gurney
Robert Klein
Sophia Kuo
Nicholas Paoni
Victoria Smith
Colin Watanabe
P Williams
William Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/025108 external-priority patent/WO1999028462A2/en
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/en
Priority claimed from PCT/US1999/020944 external-priority patent/WO2000015792A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/023089 external-priority patent/WO2000021996A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE458050T1 publication Critical patent/ATE458050T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
AT99960624T 1998-12-01 1999-11-30 Promotion oder inhibition von angiogenese und kardiovaskularisation ATE458050T1 (de)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
PCT/US1998/025108 WO1999028462A2 (en) 1997-12-03 1998-12-01 Polypeptides and nucleic acids encoding the same
US11285098P 1998-12-16 1998-12-16
US11555499P 1999-01-12 1999-01-12
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US12395799P 1999-03-12 1999-03-12
US13144599P 1999-04-28 1999-04-28
US13428799P 1999-05-14 1999-05-14
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14103799P 1999-06-23 1999-06-23
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
PCT/US1999/020594 WO2000015666A2 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumors
PCT/US1999/020944 WO2000015792A2 (en) 1998-09-14 1999-09-13 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/023089 WO2000021996A2 (en) 1998-10-13 1999-10-05 Methods and compositions for inhibiting neoplastic cell growth
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
ATE458050T1 true ATE458050T1 (de) 2010-03-15

Family

ID=37398593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960624T ATE458050T1 (de) 1998-12-01 1999-11-30 Promotion oder inhibition von angiogenese und kardiovaskularisation

Country Status (9)

Country Link
EP (1) EP1135485B1 (de)
JP (3) JP3695642B2 (de)
KR (1) KR100529270B1 (de)
AT (1) ATE458050T1 (de)
AU (1) AU771751C (de)
CA (1) CA2347835A1 (de)
IL (1) IL202176A0 (de)
MX (1) MXPA01005169A (de)
WO (1) WO2000032221A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
ES2286843T3 (es) 1997-01-14 2007-12-01 Human Genome Sciences, Inc. Receptores 6 alfa y 6 beta del factor de necrosis tumoral.
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69839401T2 (de) 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
EP1064382B1 (de) 1998-03-17 2008-08-20 Genentech, Inc. Zu vegf und bmp1 homologe polypeptide
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
CA2350776C (en) 1998-11-10 2011-05-03 Emory University Novel mitogenic regulators
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
CA2354610A1 (en) * 1998-12-09 2000-06-15 Shionogi & Co., Ltd. Human secretory phospholipase a2
EP1155117A4 (de) * 1998-12-30 2003-05-14 Millennium Pharm Inc Sekretierte proteine und nukleinsäuren die diese kodieren
KR100553300B1 (ko) * 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
CA2366087A1 (en) * 1999-03-11 2000-09-14 Mount Sinai Hospital Sialic acid-binding ig-like lectin (siglec) gene; ob-binding protein like (ob-bpl)
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
ES2295040T3 (es) * 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
AU3902600A (en) * 1999-09-15 2001-04-17 Genentech Inc. Compositions and methods for the treatment of immune related diseases
HUP0203408A3 (en) * 1999-12-09 2005-01-28 Sankyo Co Method of testing remedy or preventive for hyperlipemia
EA008480B1 (ru) * 2000-01-12 2007-06-29 Йейл Юниверсити Выделенный полинуклеотид (варианты), содержащий его вектор и клетка-хозяин, кодируемый им полипептид рецептора nogo, уменьшающий опосредованное этим рецептором ингибирование роста аксонов (варианты), выделенное антитело и фармацевтическая композиция на их основе
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2001064856A2 (en) * 2000-02-28 2001-09-07 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
KR20020093053A (ko) 2000-04-21 2002-12-12 다케다 야쿠힌 고교 가부시키가이샤 신규 인슐린/ｉｇｆ/릴랙신 패밀리 폴리펩티드 및 그의ｄｎａ
AU2001271973A1 (en) * 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PT1325130E (pt) 2000-10-06 2010-05-31 Biogen Idec Inc Homólogos do receptor de nogo
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2002057448A1 (en) * 2000-12-27 2002-07-25 Daiichi Fine Chemical Co., Ltd. Novel peptides and activities thereof
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003006687A2 (en) * 2001-07-10 2003-01-23 Medigene Ag Novel target genes for diseases of the heart
AU2002335054A1 (en) * 2001-12-19 2003-07-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2006501812A (ja) * 2002-03-01 2006-01-19 ブラッド センター リサーチ フオンデーシヨン Ｋｕ−７０由来のｂａｘ抑制ペプチド類および損傷細胞を保護するためのその使用
JPWO2003083114A1 (ja) * 2002-03-28 2005-08-04 アステラス製薬株式会社 アンジオポエチン関連増殖因子
AU2003246085A1 (en) * 2002-06-28 2004-01-19 Takeda Chemical Industries, Ltd. Diagnostics/preventives/remedies for respiratory diseases
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
WO2005068497A1 (en) * 2004-01-06 2005-07-28 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Iis: a novel ifn-gamma-inducible protein, member of the secretoglobin family, that modulates cellular invasion and migration
EP1904091A4 (de) 2005-07-07 2009-12-23 Univ Yale Zusammensetzungen und verfahren zur unterdrückung der axonalen wachstumshemmung
CA2951234C (en) 2014-06-06 2022-05-31 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10690674B2 (en) 2015-06-03 2020-06-23 Bristol-Myers Squibb Company Anti-GITR antibodies for cancer diagnostics
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
CN109136275B (zh) * 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化gitr基因改造动物模型的制备方法及应用
CN114507677B (zh) * 2022-02-16 2023-09-05 中国人民解放军空军军医大学 Ndufs1基因在治疗心梗后心衰中的应用和相关产品
EP4484444A1 (de) * 2023-06-28 2025-01-01 Centre National de la Recherche Scientifique Protein und fragmente davon und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
WO1995029242A1 (en) * 1994-04-26 1995-11-02 The Children's Medical Center Corporation Angiostatin and method of use for inhibition of angiogenesis
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
AU716889B2 (en) * 1995-11-17 2000-03-09 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide

Also Published As

Publication number Publication date
JP3695642B2 (ja) 2005-09-14
KR20010086070A (ko) 2001-09-07
MXPA01005169A (es) 2002-07-02
WO2000032221A3 (en) 2000-11-23
JP2005046146A (ja) 2005-02-24
AU1748200A (en) 2000-06-19
AU771751C (en) 2006-04-06
JP2003524385A (ja) 2003-08-19
JP2006006329A (ja) 2006-01-12
AU771751B2 (en) 2004-04-01
EP1135485B1 (de) 2010-02-17
CA2347835A1 (en) 2000-06-08
JP4358159B2 (ja) 2009-11-04
WO2000032221A2 (en) 2000-06-08
IL202176A0 (en) 2010-06-16
JP3803681B2 (ja) 2006-08-02
EP1135485A2 (de) 2001-09-26
KR100529270B1 (ko) 2005-11-21

Similar Documents

Publication Publication Date Title
ATE458050T1 (de) Promotion oder inhibition von angiogenese und kardiovaskularisation
WO2000053753A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2002008284A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
WO2000053757A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053752A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2001055307A8 (en) Nucleic acids, proteins, and antibodies
DE69635444D1 (de) Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren
DK1032668T3 (da) Fibroblast vækstfaktor 19
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2001025433A3 (en) Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
DE60038740D1 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung
WO2001040464A8 (en) Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
EP1734051A3 (de) Zusammensetzung und Verfahren zur Diagnose eines Tumors
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055449A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties